Seer, Inc. Class A SEER 深 沪
交易中 05-11 12:09:12 美东时间
1.87
+0.005
+0.27%
华盛通- 最 高1.92
- 今 开1.85
- 成交量 3.34万股
- 最 低 1.85
- 昨 收 1.865
- 总市值 11.68万
- 52周最高 2.41
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 1.65
- 委 比 -70.33%
- 总股本 6.24万
- 历史最高 86.55
- 量 比 0.16
- 振 幅 3.75%
- 历史最低 1.10
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Seer Shares Jump On Takeover Proposal
Seer, Inc. (NASDAQ:SEER) shares are trading higher Monday after the company announced that the Radoff-JEC Group submitted a non-binding proposal to acquire the company.
04-13 22:36
Seer Joins Thermo Fisher Tools In Large-Scale Proteomics Effort
Seer Proteograph platform joins Singapore study to profile 10,000 samples, integrating data for disease research and risk modeling.
04-09 20:01
Seer Q4 EPS $(0.29) Beats $(0.32) Estimate, Sales $4.201M Miss $4.600M Estimate
Seer (NASDAQ:SEER) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 21.62 percent increase over losses of $(0.37) per share from the same
02-27 05:13
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
康宁杰瑞制药-B(09966)：JSKN003获美国FDA授予用于治疗GC/GEJ的孤儿药资格认定
康宁杰瑞制药-B(09966)发布公告，JSKN003已获美国食品药品监督管理局(FDA)授予孤儿药资格认定(ODD)，用于治疗胃癌及胃食管结合部癌(GC/G...
2025-07-29 08:21
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
Seer and Korea University launch a large-scale proteomics study to identify early-onset cancer biomarkers in young adults, using Seer's Proteograph ONE Assay and advanced mass spectrometry. The three-year initiative aims to analyze 20,000 plasma samples, leveraging deep proteomic insights and AI-driven analytics to improve early cancer detection and outcomes.
2025-06-01 11:00
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
Seer, Inc. launched its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument, offering scalable, high-resolution, mass spec-based proteomics. The suite significantly improves throughput, efficiency, and affordability, enabling large-scale proteomic studies. Key advancements include processing over 1,000 samples weekly, reducing costs by 60%, and enhanced automation for reproducibility. The product will be available in June 2025.
2025-05-29 11:00
